Prelude Therapeutics (PRLD) EBIT Margin (2024 - 2026)

Prelude Therapeutics (PRLD) posted EBIT Margin of 309.54% for Q1 2026, down 0.63% sequentially from 307.59% in Q4 2025.

Prelude Therapeutics (PRLD) EBIT Margin (2024 - 2026) Analysis & Trends

Prelude Therapeutics has reported EBIT Margin for 3 years, with the latest figure at 309.54% in Q1 2026.

Quarterly EBIT Margin changed N/A year-over-year to 309.54% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 503.21% (changed N/A YoY) and the FY2025 annual result came in at 861.33%, up 113458.0% from the prior year.
EBIT Margin eased to 309.54% in Q1 2026 per PRLD's latest filing, from 307.59% in the prior quarter.
Over five years, EBIT Margin peaked at 307.59% in Q4 2025 and troughed at 1145.87% in Q3 2024.
A 3-year average of 584.58% and a median of 314.12% in 2025 frame the typical range for EBIT Margin.
The widest YoY moves for EBIT Margin: up 83174 bps in 2025, down 53819 bps in 2025.
Over 3 years, EBIT Margin stood at 845.78% in 2024, then soared by 64 bps to 307.59% in 2025, then dropped by 1 bps to 309.54% in 2026.
According to Business Quant data, EBIT Margin over the past three periods registered 309.54%, 307.59%, and 314.12% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-105.20%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	Prelude Therapeutics	442.91 Mn	162.28 Mn	-	-270.93%

Download Data